Success Metrics

Active Trials
2(40%)

Phase Distribution

Ph phase_1
5
100%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Terminated(1)
Other(2)

Detailed Status

unknown2
Active, not recruiting1
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

unknown240%
active_not_recruiting120%
recruiting120%
withdrawn120%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_1

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

NCT05565807
withdrawnphase_1

An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis

NCT05692908
active_not_recruitingphase_1

Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

NCT05308225
unknownphase_1

Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors

NCT05584709
unknownphase_1

Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis

NCT04316442

Clinical Trials (5)

Showing 5 of 5 trials
NCT05565807Phase 1

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Recruiting
NCT05692908Phase 1

An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis

Withdrawn
NCT05308225Phase 1

Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Active Not Recruiting
NCT05584709Phase 1

Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors

Unknown
NCT04316442Phase 1

Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis

Unknown

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5